Solid tumor treatments in San Francisco, California

The UCSF Pediatric Solid Tumor Program, located at 1825 4th Street in San Francisco, California, is a world-class institution dedicated to providing specialized evaluation, diagnosis, and care for children, teens, and young adults with solid tumors. Our team of experts handles a range of conditions, from common to rare, including neuroblastoma, hepatoblastoma, bone and soft tissue sarcomas, Wilms' tumors, and other cancers. We also care for patients with relapsed cancers and are known globally for taking on rare and challenging cases. At UCSF, we believe in tailoring cancer therapy to each patient's unique disease, offering high-quality, targeted care that is precise, effective, and compassionate. Our program utilizes advanced diagnostic tools, including genetic tests developed in-house, and provides access to new treatments not widely available elsewhere. As a member of the Oncology Group Phase 1/Pilot Consortium, we are at the forefront of developing new therapies for pediatric cancers.

The UCSF Hematology, Blood & Marrow Transplant, and Cellular Therapy (HBC) Program, located at 400 Parnassus Avenue in San Francisco, California, is a renowned institution dedicated to providing advanced treatment options with care and compassion for patients with blood disorders and cancers. Patients from around the world seek treatment from our specialized providers, who offer innovative therapies and the opportunity to participate in cutting-edge clinical trials, including CAR T-cell therapy. As part of the UCSF Helen Diller Family Comprehensive Cancer Center, our program offers a wide range of services to support cancer patients, including support groups, exercise classes, psychosocial support, and symptom management. Our research teams are at the forefront of cell-based immunotherapy for cancer, with a focus on developing breakthrough treatments for various blood cancers and solid tumors.

Dr. Hyunseok Kang is a medical oncologist and specialized cancer researcher located at 1600 Divisadero Street in San Francisco, California. Dr. Kang, also known as Hyu, specializes in treating adults with head and neck cancers using conventional chemotherapy, targeted therapy, and immunotherapy. He is actively involved in researching new therapies for head and neck cancers through clinical trials, focusing on improving the efficacy of immune checkpoint inhibitors and developing targeted approaches for rare cancers of the head and neck. Dr. Kang earned his medical degree at Yonsei University College of Medicine in Seoul, South Korea, and completed his residency and fellowship in internal medicine, hematology, and medical oncology in the United States. He is a fellow of the American College of Physicians and a member of several oncology and cancer research organizations. Prior to joining UCSF Health, Dr. Kang worked at the Johns Hopkins Hospital and served as an assistant professor of oncology at the Johns Hopkins University School of Medicine. He is currently involved in various research studies aimed at improving cancer treatment outcomes, including studies on adenoid cystic carcinoma, advanced solid tumors, and squamous cell carcinoma of the head and neck.

Dr. Rahul Aggarwal, MD is a renowned developmental therapeutics specialist, genitourinary oncologist, and cancer researcher located at 1825 4th Street, San Francisco, California, United States. He is affiliated with the UCSF Helen Diller Family Comprehensive Cancer Center and serves as the director of the UCSF STAND Clinic, providing comprehensive care to men undergoing hormone therapy for prostate cancer. Dr. Aggarwal specializes in enrolling patients in early-phase clinical trials for advanced solid tumor malignancies, focusing on hormonal treatment strategies and molecular imaging techniques. He is a recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award and is a member of the American Society of Clinical Oncology. Dr. Aggarwal is dedicated to advancing cancer research and providing cutting-edge care to his patients. Visit Dr. Rahul Aggarwal, MD for expert treatment and compassionate care in the field of oncology.

Dr. Adil Daud, MD is an institution located at 1600 Divisadero Street, San Francisco, California, United States. This institution is a doctor specializing in oncology and melanoma, with a focus on immunotherapy research. Dr. Daud is also a history and literature buff. He is the co-director of the Melanoma Center and conducts research to better understand melanoma biology and develop new treatments. Dr. Daud has led numerous clinical trials expanding the use of gene therapy for melanoma. He has received awards such as the Young Investigator Award from the American Society of Clinical Oncology and has been recognized as a Castle Connolly Top Doctor. The institution is conducting studies on advanced melanoma and other solid tumors, as well as investigating the genes predictive of response to anti-PD-1 therapy in melanoma. Dr. Daud and his team at UCSF Health are dedicated to advancing treatments for advanced skin cancer and working towards a malaria-free world through partnerships and innovative healthcare solutions. For the best experience, it is recommended to use Chrome or Firefox when visiting the UCSF Health website.

Dr. Katy K. Tsai, MD is a medical oncologist located at 1600 Divisadero Street in San Francisco, California. Specializing in treating melanoma and other skin cancers, Dr. Tsai also conducts clinical trials with her colleagues in cutaneous oncology to find new and improved therapies for patients with advanced melanoma or head and neck cancers. With a background in comparative literature from Brown University and a medical degree from Brown as well, Dr. Tsai has a passion for researching quality of life and outcomes for patients undergoing immunotherapy. She is a member of the American Society of Clinical Oncology and was born in Taiwan and raised in Toronto. Dr. Tsai is currently involved in several clinical trials focusing on advanced solid tumors and melanoma treatment. At UCSF Health, Dr. Tsai and her team are dedicated to working towards a malaria-free world through partnerships with various organizations and innovative healthcare solutions. For the best experience, it is recommended to use Chrome or Firefox when visiting the UCSF Health website.

Dr. Pamela Munster, MD is a medical oncologist and the co-director of the Center for BRCA Research located in San Francisco, California, United States. She is currently conducting research on the effect of Denosumab in preventing breast cancer in women with a BRCA1 germline mutation. The institution also focuses on studying combination therapy in cancers with mutations in DNA repair genes and evaluating the efficacy and safety of various treatments for advanced solid tumors. Additionally, Dr. Munster and her team are involved in a study of Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient tumors. The institution is dedicated to advancing cancer research and providing the best possible care for patients. Please note that for the best experience, it is recommended to use Chrome or Firefox when visiting the UCSF Health website.

Dr. David Oh, MD, PhD is a medical oncologist located at 1825 4th Street in San Francisco, California, United States. He specializes in caring for patients undergoing novel immunotherapies for cancer treatment, particularly focusing on prostate and bladder cancers. Dr. Oh conducts research to enhance cancer immunotherapies and leads clinical trials to evaluate new treatments for solid tumors. He is a member of various prestigious medical associations and has received awards for his contributions to oncology research. Additionally, UCSF Health, where Dr. Oh practices, is dedicated to advancing healthcare innovations to combat diseases like malaria through partnerships with global organizations. For the best browsing experience, it is recommended to use Chrome or Firefox instead of Internet Explorer.

Dr. W. Clay Gustafson, MD, located at 1825 4th Street in San Francisco, California, is a world-class institution specializing in pediatric cancer care. Dr. Gustafson, a dedicated physician-scientist, is passionate about finding innovative treatments for pediatric solid tumors, with a particular focus on neuroblastoma. With a background in biochemistry and genetics, Dr. Gustafson leads research efforts to develop unique therapies for cancer. In addition to his research, Dr. Gustafson also provides expert care to children through phase I and II clinical trials for neuroblastoma. At Dr. W. Clay Gustafson's institution, patients can expect stress-free visits with accommodations and support throughout their journey. The team of specialists at this institution is equipped to handle a wide range of conditions, from common to rare, ensuring that each child receives extraordinary care. Dr. Gustafson's dedication to finding personalized solutions for each patient reflects his belief that individualized therapy can lead to creative solutions to challenging problems like curing cancer.